IDEXX Laboratories has made its Cancer Dx panel, a rapid, non‑invasive test that can detect canine lymphoma up to eight months before clinical signs appear, available to veterinary practices across the United Kingdom. The panel’s launch follows the company’s March 2025 introduction in the United States and Canada, where it has already attracted 17 % of submissions from competitive laboratory customers and has been integrated by nearly 6,000 veterinary practices.
The panel delivers results within 2–3 business days in the United States and Canada and 3–5 business days in the United Kingdom, with a sensitivity of 79 % and a specificity of 99 %. Pricing in the United States starts at $15 per test, positioning the product as an affordable, high‑value option for routine screening. By adding a consumable product to its “Technology for Life” ecosystem—comprising instruments, consumables, and cloud‑based practice‑management software—IDEXX aims to lock in customers and generate recurring revenue streams.
Early detection of lymphoma allows veterinarians to initiate treatment decisions sooner, potentially improving patient outcomes and increasing diagnostic intensity per visit. The launch is expected to reinforce IDEXX’s competitive advantage over reference laboratories that currently handle lymphoma testing, while also expanding the company’s Companion Animal Group revenue base. In the most recent quarter, the Companion Animal Group generated $919.84 million, Water diagnostics contributed $45.32 million, and Livestock, Poultry, and Dairy (LPD) added $28.60 million, underscoring the company’s diversified revenue mix.
CEO Jay Mazelsky highlighted the strategic importance of the new panel, stating, “We’re proud to be at the forefront of early cancer detection in dogs and delighted to expand access to reliable cancer testing in the United Kingdom.” His comments reflect IDEXX’s focus on innovation and its commitment to providing veterinarians with tools that improve animal health and strengthen the company’s market position.
The UK launch aligns with IDEXX’s broader strategy to grow its Cancer Dx portfolio, which includes plans to expand the panel to cover the majority of canine cancer cases over the next three years. By entering the UK market, IDEXX taps a region where 71 % of pet owners express interest in cancer screening, positioning the company to capture a new customer base of veterinary practices that rely on rapid, point‑of‑care testing.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.